Webinar
22.07.2026
Design Once, Adapt Smartly Aligning NICE and JCA e...

As NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...

Read more
Articles
06.07.2026
Why Pricing Strategy Must Start Earlier: Linking E...

Pricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...

Read more
Webinar
01.07.2026
Dissecting the First EU Joint Clinical Assessment ...

The first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical i...

Read more
Poster
10.06.2026
A comparison of conflict-of-interest (CoI) managem...

Expert contributions are critical to health technology assessment (HTA), particularly in rare diseas...

Read more
Insider Insights
09.06.2026
Spain HTA reform 2026: Will Your Evidence Measure ...

Spain has published Royal Decree 415/2026[1], setting out a new national framework for health techno...

Read more
Articles
06.05.2026
Playing the Long Game: How Early Scientific Advice...

Early HTA scientific advice reduces price and reimbursement risk by informing ev...

Read more
Articles
13.04.2026
Don’t Wait for a JSC: Unlocking Value Through H...

While missing an EU Joint Scientific Consultation (JSC) is suboptimal, the greater strategic concern...

Read more
Articles
30.03.2026
From Evidence to Negotiation: Succeeding Under Ita...

From 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...

Read more
Articles
19.01.2026
If You’re a Market Access Lead in 2026: How to...

The year 2026 marks a significant milestone for the European Union’s (EU) Health Tec...

Read more
News
03.12.2025
Joint Scientific Consultations 2026 – key dates ...

The HTA Coordination Group (HTACG) has now confirmed the 2026 request periods for joint scientific c...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.